Alira Health

Alira Health

GMP Manufacturing and IND-Enabling Studies of a Recombinant Hyperimmune Globulin Targeting SARS-CoV-2

The last two years have brought forward tremendous advances in the development of prophylactic and therapeutic approaches for the treatment of SARS-CoV-2 infections. Vaccines, monoclonal antibodies, antiviral agents, convalescent plasma, immunomodulators and other investigational therapies have either been approved or are at the investigational stage.

While serious outcomes of disease are no longer common, transmission remains high and the emergence of new variants capable of evading immunosurveillance induced by vaccination or escaping the neutralization capabilities of existing monoclonal antibodies. Thus, new medicines continue to be needed. Antibodies have been shown to be an effective treatment, and an intriguing approach is to use polyclonal (a mixture of different molecules) vs. monoclonal (a single molecule) antibodies. Indeed, the use of convalescent plasma was initiated to treat those most severely affected by infection, with the intent of delivering human polyclonal antibodies capable of neutralizing the virus.

Limitations thereof, however, are that convalescent plasma donated by vaccinated of previously infected individuals contain polyclonal antibodies against a few variants and are not effective against variants from the 8 SARS-CoV-2 clades thus far identified.   

Is it possible to create a ‘super’ mixture of antibodies reactive against all SARS-CoV-2 variants?  The answer is yes.  As described by Rena Mizrahi and her colleagues at GigaGgen, Inc., in South San Francisco, CA, it is now possible to produce such an antibody mixture using recombinant DNA technology. Titled “GMP Manufacturing and IND-Enabling Studies of a Recombinant Hyperimmune Globulin Targeting SARS-CoV-2” and published in the peer-reviewed journal Pathogens, this report by Dr. Mizrahi and her team makes for an interesting read into the development of recombinant oligoclonal antibodies against SARS-CoV-2. In addition to her colleagues at GigaGgen and collaborating institutions, Dr. Mizrahi’s team includes the following members of our team: 

  • Steven Chamow, Senior Vice President, CMC 
  • Wendy Lin, Consultant 
  • Charles Olsen, Consultant 
Scientific Articles
Published on:
August 2, 2022
Written by:
Steven Chamow, Wendy Lin, Charles Olsen
About Alira Health

As experienced CMC consultants, we can help you navigate the complex demands of product development and manufacture. We can provide your company with strategic advice and solutions designed to ensure success across the full product lifecycle.

Related news

Webinars February 5, 2024
What Comes After the mRNA Vaccines?
In the third episode of VacciTalks, we’ll discuss these new alternatives to mRNA vaccines and the promise they hold.
Drug Development Vaccines
Scientific Articles November 20, 2023
Therapeutic IgG-Like Bispecific Antibodies: Modular Versatility and Manufacturing Challenges
Our experts conducted a deep evaluation of IgG-like bsAbs including general advantages and disadvantages compared with MAbs and more.
CMC
Scientific Articles November 20, 2023
Immunoglobulin Fc-Fusion Proteins
Our experts published a series of articles in BioProcess International reviewing the state of the art of Fc – fusion proteins, including their structure and molecular design, manufacturing(...)
CMC
Scientific Articles November 14, 2023
Capture of CH1-Containing Bispecific Antibodies: Evaluating an Alternative to Protein A
In the article our team investigated the use of an alternative purification method for BsAbs – a commercially available CaptureSelect CH1-XL affinity resin.
CMC Drug Development
Webinars October 18, 2023
The Process of CDMO Selection for Antibody Development: Matching Capabilities to Need
In this webinar, you'll learn how to identify key solution features, define patient experience expectations, generate evidence, and more!
CDMO CMC
Events September 27, 2023
Advances in Biologics and CGT
We are excited to share that we will be joining the Networking Reception: Advances in Biologics and CGT hosted by Catalent.
Biologics CMC
Scientific Articles September 21, 2023
Essential Elements of Technology Transfer
Peter Alexander, Senior Consultant, CMC, co-authored an article about technology transfer categories, essential elements, and documentation.
CDMO CMC
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.